Invention Publication
- Patent Title: MASP INHIBITORY COMPOUNDS AND USES THEREOF
-
Application No.: US18299600Application Date: 2023-04-12
-
Publication No.: US20240124522A1Publication Date: 2024-04-18
- Inventor: Donald Bierer , Ingo Flamme , Dmitry Zubov , Thomas Neubauer , Adrian Tersteegen , Cathleen Juhl , Marie Glatz , Jan Dreher , Simon Holton , Carsten Terjung , Lars Baumann , Thorsten Poethko , Jiancheng Xiong , Yibo Qiu
- Applicant: Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Leverkusen
- Assignee: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Leverkusen; DE Berlin
- Priority: WO TCN19085791 2019.05.07
- The original application number of the division: US17138447 2020.12.30
- Main IPC: C07K7/08
- IPC: C07K7/08 ; A61K38/10 ; A61K45/06 ; A61P13/12
Abstract:
The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
Information query
